JONATHAN MCCRARY: Open Payments
NPI 1962972968 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,169 in 113 payments from 22 companies in 2025. Trend: 2023 $2,898 · 2024 $2,790 · 2025 $2,169
Food & beverage: $2,169
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $258 |
| Madrigal Pharmaceuticals | 10 | $224 |
| ABBVIE INC. | 15 | $216 |
| QOL Medical, LLC | 7 | $154 |
| Ardelyx, Inc. | 7 | $142 |
| Ipsen Biopharmaceuticals, Inc | 7 | $141 |
| Aimmune Therapeutics, Inc. | 7 | $118 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $116 |
| GENZYME CORPORATION | 5 | $113 |
| Lilly USA, LLC | 6 | $112 |
Products named: ENTYVIO, REZDIFFRA, DUPIXENT, Sucraid, IBSRELA, IQIRVO, TREMFYA, ZENPEP.
Industry payments across AL — which companies pay providers there.
